

23rd September, 2024

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
----------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 about Bajaj Healthcare Limited entering into a Development and Supply Agreement for an Active Pharmaceutical Ingredient (API) with a European Entity

This is to inform you that Bajaj Healthcare Limited (“the Company”) has entered into a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European Entity. This API after its development will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication.

The trust reposed in our Company by the EU partner for sourcing clinical trial quantities is a testimony of the Company’s development and manufacturing capabilities along with the Good Manufacturing Practices (GMP) compliance at Company’s manufacturing units.

Based on the outcome of these trials, the supplies will be done from the Company’s FDA approved manufacturing facility situated at Savli, Vadodara.

Further, till the outcome of these trials, it will be revenue neutral.

Kindly take the same on record.

Thanking You,

**For and Behalf of Board of Director of
Bajaj Healthcare Limited**

**Anil Jain
Managing Director
DIN: 00226137**

BAJAJ HEALTHCARE LIMITED